Adcirca is used to treat pulmonary arterial hypertension. Learn about side effects, interactions and indications. Pulmonary arterial hypertension (PAH) is a serious condition that affects blood flow in the lungs. Tadalafil, a drug that helps widen blood vessels, is used to treat PAH and has advantages over similar drugs like sildenafil, including once-daily dosing and longer-lasting effects. Adcirca (tadalafil) is a once-daily oral therapy approved in the U.S. to improve exercise ability in people with pulmonary arterial hypertension (PAH). In PAH, the pulmonary arteries, which carry blood from the heart to the lungs, become narrowed, causing blood pressure to rise. Background— Treatment options for pulmonary arterial hypertension target the prostacyclin, endothelin, or nitric oxide pathways. Tadalafil, a phosphodiesterase type-5 inhibitor, increases cGMP, the final mediator in the nitric oxide pathway. Methods and Results— In this 16-week, double-blind, placebo-controlled study, 405 patients with pulmonary arterial hypertension (idiopathic or. Abstract Pulmonary arterial hypertension (PAH) is a chronic and disabling condition characterized by an elevated pulmonary vascular resistance and an elevated mean pulmonary arterial pressure. Despite recent improvements in treatment availability, PAH remains challenging to treat, burdensome for patients, and ultimately incurable. Tadalafil is a phos-phodiesterase-5 inhibitor that is. Tadalafil (Pulmonary Hypertension) reference guide for safe and effective use from the American Society of Health-System Pharmacists (AHFS DI). TADALAFIL (tah DA la fil) treats pulmonary arterial hypertension (PAH), a condition that causes high blood pressure in the lungs. It works by relaxing your blood vessels and lowering the blood pressure in your lungs, which makes it easier for your heart to pump blood to the rest of your body. It can also help you breathe easier and be more active. Tadalafil (Adcirca) Tadalafil is a medication that treats pulmonary artery hypertension by widening blood vessels in the lungs, which improves heart function and increase exercise ability. ADCIRCA (tadalafil), an oral treatment for pulmonary arterial hypertension, is a selective inhibitor of cyclic guanosine monophosphate (cGMP)–specific phosphodiesterase type 5 (PDE5). Tadalafil at this dose of 1 mg/kg/day appears well tolerated in neonates and infants with PH secondary to BPD and correlates with improvements in pulmonary artery pressures. Further studies evaluating tadalafil in comparison to other phosphodiesterase-5 inhibitors in neonates with PH secondary to BPD are warranted.